Investor Presentaiton

Immunology LPA₁ Sotyktu Addressing high unmet medical need in Immunology Asset Approved Registrational+ CD19 NEX T Exploratory/PoC Studies* Moderate-to-severe Psoriasis Psoriatic Arthritis Alopecia Areata SOTYKTUO (deucravacitinib)ets Sjögren's Syndrome Systemic Lupus Moderate-to-severe Erythematosus Moderate-to-severe Crohn's ZEPOSIA. Ulcerative Colitis Disease (ozanimod) capsules 0.92 mg CD19 NEX T cendakimab LPA, Antagonist Ill Bristol Myers Squibb™ 1. Japan registrational trial; † ongoing or initiating 2023/2024 • Eosinophilic Esophagitis Eosinophilic Gastroenteritis¹ Idiopathic Pulmonary Fibrosis Progressive Pulmonary Fibrosis Severe, refractory Systemic Lupus Erythematosus Not for Product Promotional Use 56

View entire presentation